PTO/SB/21 (02-04) 3 1 2004 Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.	
TRANSMITTAL FORM (to be used for all correspondence after initial fill	Examiner Name
Total Number of Pages in This Submission	D.R. Rao Attorney Docket Number OC01625K
ENCLOSURES (Check all that apply)	
Fee Transmittal Form Fee Attached Amendment/Repty After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Exhibit A (13pgs.); Exhibit B (10pgs.); Table 4 (7pgs.); Post Card
SIGNAT	URE OF APPLICANT, ATTORNEY, OR AGENT
Firm or Individual name Palaiyur S. Kalyanaran Signature 03/29/2004	nan, Reg. No. 34,634
JUJI 271 2004	
CE	RTIFICATE OF TRANSMISSION/MAILING
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	

Typed or printed name Palaiyur S. Kalyanaraman Date Signature 03/29/2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



5

15

PATENT: OC01625K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Examiner: D. R. Rao

K. Paruch et al.

Group Art Unit: 1624

10 Serial No.:10/665,005

Filed: September 19, 2003

Atty. Docket No.: OC01625K

For: "Novel Imidazopyrazines as Cyclin:

Dependent Kinase Inhibitors"

Mail Stop: Non-Fee Amendment Commissioner for Patents

20 P. O. Box 1450

Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT

Sir:

25 This communication is in response to the restriction requirement and Office Action that the Examiner issued on March 12, 2004, in the above-identified patent application. Applicants respectfully request entry and consideration of the following Amendment and Remarks by Applicants.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks begin on page 13 of this paper.